nach oben

Pediatric Nephrology

Erschienen in:

01.03.2005 | Review

The multi-functional role of insulin-like growth factor binding proteins in bone

verfasst von: Kristen E. Govoni, David J. Baylink, Subburaman Mohan

Erschienen in: Pediatric Nephrology | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

The insulin-like growth factor (IGF) system is an important regulator of bone formation. The IGFs (IGF-I and IGF-II) are the most abundant growth factors produced by bone, and are regulated by their six high affinity binding proteins (IGFBPs). The IGFBPs are produced by osteoblasts and are responsible for transporting the IGFs and extending their half-lives. In general, IGFBP-1, -2, -4, and -6 inhibit and IGFBP-3 and –5 stimulate osteoblast function. IGFBP-4 and -5 are the most abundant IGFBPs produced by osteoblasts, and therefore they are the primary focus of this review. IGFBP-5 is an important stimulator of bone formation and may also function independently of IGFs. IGFBP-4 inhibits osteoblast function by sequestering IGF and preventing it from binding to its receptor. This review focuses on the specific IGF-dependent and IGF-independent roles of the IGFBPs in bone formation, as well as their potential mechanisms of action. In addition, discussion of the regulation of the IGFBPs by post-translational modification (i.e., proteolysis) has been included. Studies on the regulation of production and actions of IGFBPs suggest that the IGFBP system in bone is pleiotropic and capable of serving multiple effector inputs from systemic and local sources.

Mohan S, Richman C, Guo R, Amaar Y, Donahue LR, Wergedal J, Baylink DJ (2003) Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and –independent mechanisms. Endocrinology 144:929–936CrossRefPubMed

Woods KA, Camacho-Hübner C, Savage MO, Clark A (1996) Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 335:1363–1367CrossRefPubMed

Pereira Arias A, Walenkamp M-J, Hilhorst-Hofstee Y, Karperien M, Van Duyvenvoorde H, Bax J, Doorn J van, Romijn JA, Wit J-M (2003) Clinical and biochemical expression of a homozygous missense mutation in the IGF-1 gene (abstract). Abstracts of the 85th Annual Endocrine Society Meeting, Philadelphia

Walenkamp M-J, Pereira Arias A, Sluimers C, Hilhorst-Hofstee Y, Thiel S van, Karperien M, Duyvenvoorde H van, Laat J de, Doorn J van, Romijn J, Wit J-M (2003) Heterozygosity for a missense mutation (V44 M) in the IGF-I gene leads to a lower height and head circumference and a higher plasma IGF-I than observed in non-carriers (abstract). Abstracts of the 85th Annual Endocrine Society Meeting, Philadelphia

Mohan S, Baylink DJ (1999) Role of growth hormone/insulin-like growth factor axis. In: Rosen CJ, Glowacki J, Bilezikian J (eds) The aging skeleton. Academic Press, San Diego, pp 195–204

Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A (1993) Mice carrying null mutations of the genes encoding insulin-like growth factor I (IGF-I) and type 1 IGF receptor (IGFr). Cell 75:59–72CrossRefPubMed

Baker J, Liu JP, Robertson EJ, Efstratiadis A (1993) Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75:73–82CrossRefPubMed

Yakar, S, Liu J, Stannard B, Butler A, Accili D, Sauer B, LeRoith D (1999) Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 96:7324–7329CrossRefPubMed

Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu J, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D (2002) Circulating levels of IGF-I directly regulate bone growth and density. J Clin Invest 110:771–781CrossRefPubMed

10.

Mohan S, Baylink DJ (1996) Insulin-like growth factor system components and the coupling of bone formation to resorption. Horm Res 45 [Suppl 1]:59–66

11.

Rosen CJ, Donahue LR (1998) Insulin-like growth factors and bone: the osteoporosis connection revisited. Proc Soc Exp Biol Med 219:1–7PubMed

12.

Mohan S, Baylink DJ (1997) Serum insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 levels in aging and age-associated diseases. Endocrine 7:87–91PubMed

13.

Boonen S, Mohan S, Dequeker J, Aerssens J, Vanderschueren D, Verbeke G, Broos P, Bouillon R, Baylink DJ (1999) Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis. J Bone Miner Res 14:2150–2158PubMed

14.

Amaar YG, Thompson GR, Linkhart TA, Chen ST, Baylink DJ, Mohan S (2002) Insulin-like growth factor binding protein-5 (IGFBP-5) interacts with a four and a half LIM protein 2 (FHL2). J Biol Chem 277:12053–12060CrossRefPubMed

15.

Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824–854CrossRefPubMed

16.

Qin X, Strong DD, Baylink DJ, Mohan S (1998) Structure-function analysis of the human insulin-like growth factor binding protein-4. J Biol Chem 273:23509–23516CrossRefPubMed

17.

Rajaram S, Baylink DJ, Mohan S (1997) Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18:801–831CrossRefPubMed

18.

Conover CA (1996) Regulation and physiological role of insulin-like growth factor binding proteins. Endocr J 43 [Suppl]:S43–S48

19.

Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 16:3–34

20.

Mohan S, Baylink DJ (2002) IGF binding proteins are multifunctional and act via IGF-dependent and IGF-independent mechanisms. J Endocrinol 175:19–31PubMed

21.

Rechler MM (1993) Insulin-like growth factor binding proteins. Vitam Horm 47:1–114PubMed

22.

Miyakoshi N, Richman C, Qin X, Baylink DJ, Mohan S (1999) Effects of recombinant insulin-like growth factor binding protein-4 on bone formation parameters in mice. Endocrinology 140:5719–5728CrossRefPubMed

23.

Mohan S, Nakao Y, Honda Y, Landale E, Leser U, Dony C, Lang K, Baylink DJ (1995) Studies on the mechanisms by which insulin-like growth factor binding protein (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J Biol Chem 270:20424–20431CrossRefPubMed

24.

Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR (1993) Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA 90:10553–10557PubMed

25.

Gleeson LM, Chakraborty C, McKinnon T, Lala PK (2001) Insulin-like growth factor-binding protein 1 stimulates human trophoblast migration by signaling through alpha 5 beta 1 integrin via mitogen-activated protein kinase pathway. J Clin Endocrinol Metab 86:2484–2493CrossRefPubMed

26.

Richman C, Baylink DJ, Lang K, Dony C, Mohan S (1999) Recombinant human insulin-like growth factor binding protein-5 (rhIGFBP-5) stimulates bone formation parameters in vitro and in vivo. Endocrinology 140:4699–4705CrossRefPubMed

27.

Miyakoshi N, Richman C, Kasukawa Y, Linkhart TA, Baylink DJB, Mohan S (2001) Evidence that IGF-binding protein-5 functions as a growth factor. J Clin Invest 107:73–81PubMed

28.

Silha JV, Mishra S, Rosen CJ, Beamer WG, Turner RT, Powell DR, Murphy LJ (2003) Perturbations in bone formation and resorption in insulin-like growth factor binding protein-3 transgenic mice. J Bone Miner Res 18:1834–1841PubMed

29.

Kanatani M, Sugimoto T, Mishiyama K, Chihara K (2000) Stimulatory effect of insulin-like growth factor binding protein-5 on mouse osteoblast formation and osteoclastic bone-resorbing activity. J Bone Miner Res 15:902–910PubMed

30.

Jehle P, Schulten K, Jehle DR, Stracke S, Manfras B, Boehm B, Baylink DJ, Mohan S (2003) Serum levels of insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP) 1 through 6 and relationship to bone metabolism in osteoporosis patients. Eur J Intern Med 14:32–38CrossRefPubMed

31.

Bautista CM, Baylink DJ, Mohan S (1991) Isolation of a novel insulin-like growth factor (IGF) binding protein from human bone: a potential candidate for fixing IGF-II in human bone. Biochem Biophys Res Commun 176:756–763PubMed

32.

Nicolas V, Mohan S, Honda Y, Prewett A, Finkelman RD, Baylink DJ, Farley JR (1995) An age-related decrease in the concentration of insulin-like growth factor binding protein-5 in human cortical bone. Calcif Tissue Int 57:206–212PubMed

33.

Andress DL (1998) Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates phosphorylation of the IGFBP-5 receptor. Am J Physiol 274:E744–E750PubMed

34.

Delvin RD, Du Z, Buccilli V, Jogetti V, Canalis E (2002) Transgenic mice overexpressing insulin-like growth factor binding protein-5 display transiently decreased osteoblastic function and osteopenia. Endocrinology 143:3955–3962CrossRefPubMed

35.

Andress DL (2001) IGF-binding protein-5 stimulates osteoblast activity and bone accretion in ovariectomized mice. Am J Physiol Endocrinol Metab 218:E283–E288

36.

Bauss F, Lang K, Dony C, Kling L (2001) The complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its binding protein-5 (IGFBP-5) induces local bone formation in murine calvariae and in rat cortical bone after local or systemic administration. Growth Horm IGF Res 11:1–9CrossRef

37.

Lotinun S, Sibonga JD, Turner T (2002) Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression. Endocrine 17:29–36CrossRefPubMed

38.

Schedlich LJ, Young TF, Firth SM, Baxter RC (1998) Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J Biol Chem. 273:18347–18352

39.

Schedlich LJ, Le Page SL, Firth SM, Briggs JL, Jans DA, Baxter RC (2000) Nuclear import of insulin-like growth factor-binding protein-3 and −5 is mediated by the importin beta subunit. J Biol Chem 275:23462–23470CrossRefPubMed

40.

Mohan S, Thompson GR, Amaar YG, Hathaway G, Tschesche H, Baylink DJ (2002) ADAM-9 is an insulin-like growth factor binding protein-5 protease produced and secreted by human osteoblasts. Biochemistry 41:15394–15403CrossRefPubMed

41.

Andress DL, Loop SM, Zapf J, Kiefer MC (1993) Carboxy-truncated insulin-like growth factor binding protein-5 stimulates mitogenesis in osteoblast-like cells. Biochem Biophys Res Commun 195:25–30CrossRefPubMed

42.

Zhang, M, Faugere MC, Malluche H, Rosen CJ, Chernausek SD, Clemens TL (2003) Paracrine overexpression of IGFBP-4 in osteoblasts of transgenic mice decreases bone turnover and causes global growth retardation. J Bone Miner Res 18:836–843PubMed

43.

Miyakoshi N, Qin X, Richman C, Srivastava AK, Baylink DJ, Mohan S (2001) Studies on the mechanism by which systemically administered insulin-like growth factor binding protein-4 increases bone formation parameters in mice. Endocrinology 142:2641–2648CrossRefPubMed

44.

Qin X, Sexton C, Byun D, Strong D, Baylink D, Mohan S (2002) Differential regulation of pregnancy associated plasma protein (PAPP)-A during pregnancy in human and mouse. Growth Horm IGF Res 12:359–365CrossRefPubMed

45.

Conover CA, Bale LK, Overgaard MT, Johnstone EW, Laursen UH, Fuchtbauer EM, Oxvig C, Van Deursen J (2004) Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development. Development 131:1187–1194CrossRefPubMed

46.

Yan T, Wergedal J, Zhou Y, Mohan S, Baylink DJ, Strong DD (2001) Inhibition of human osteoblast marker gene expression by retinoids is mediated in part by insulin-like growth factor binding protein-6. GH and IGF Res 11:368–377CrossRef

47.

Zhou Y, Mohan S, Linkhart TA, Baylink DJ, Strong DD (1996) Retinoic acid regulates insulin-like growth factor-binding protein expression in human osteoblast cells. Endocrinology 137:975–983CrossRefPubMed

48.

Strong DD, Chen ST, Linkhart TA, Yan T, Baylink DJ, Mohan S (2002) IGF binding protein-6 (BP-6) markedly inhibits osteoblast differentiation: evidence for a intracrine mechanism involving nuclear localization utilizing a novel nuclear localization signal (NLS) (abstract). Abstracts of the 84th Annual Meeting Endocrine Society, San Francisco

49.

Strong DD, Linkhart TA, Gunn Y, Kim R, Rung-Aroon J, Mohan S, Baylink DJ, Amaar Y (2003) Evidence that the mechanism whereby insulin-like growth factor binding protein (IGFBP)-6 markedly inhibits osteoblast differentiation is through sequestration of an activator of osteoblast differentiation, the LIM mineralization protein-1 (LMP-1) (abstract). Abstracts of the 25th Annual Meeting of American Society for Bone and Mineral Research, Minneapolis

50.

Boden SD, Liu Y, Hair GA, Helms JA, Hu D, Racine M, Nanes MS, Titus L (1998) LMP-1, a LIM-domain protein, mediates BMP-6 effects on bone formation. Endocrinology 139:5125–5134CrossRefPubMed

51.

Ernst M, Rodan GA (1990) Increased activity of insulin-like growth factor (IGF) in osteoblastic cells in the presence of growth hormone (GH): positive correlation with the presence of the GH-induced IGF-binding protein BP-3. Endocrinology 127:807–814PubMed

52.

Conover CA, Khosla S (2003) Role of extracellular matrix in insulin-like growth factor (IGF) binding protein-2 regulation of IGF-II action in normal human osteoblasts. GH and IGF Res 13:328–335CrossRef

53.

Eckstein F, Pavicic T, Nedbal S, Schmidt C, Wehr U, Rambeck W, Wolf E, Hoeflich A (2002) Insulin-like growth factor-binding protein-2 (IGFBP-2) overexpression negatively regulates bone size and mass, but not density, in the absence and presence of growth hormone/IGF-I excess in transgenic mice. Anat Embryol (Berl) 206:139–148

54.

Campbell PG, Novak JF (1991) Insulin-like growth factor binding protein inhibits IGF action in human osteosarcoma cells. J Cell Physiol 149:293–300PubMed

55.

Mohan S, Bautista CM, Wergedal J, Baylink DJ (1989) Isolation of an inhibitory insulin-like growth factor (IGF) binding protein from bone cell-conditioned medium: a potential local regulator of IGF action. Proc Natl Acad Sci USA 86:8338–8342PubMed

Titel: The multi-functional role of insulin-like growth factor binding proteins in bone
verfasst von: Kristen E. Govoni
David J. Baylink
Subburaman Mohan
Publikationsdatum: 01.03.2005
Verlag: Springer-Verlag
Erschienen in: Pediatric Nephrology / Ausgabe 3/2005
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-004-1658-y

Neu im Fachgebiet Pädiatrie

23.04.2024 | Typ-1-Diabetes | Nachrichten

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The multi-functional role of insulin-like growth factor binding proteins in bone

Abstract

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2005

Recombinant insulin-like growth factor-1 as a therapy for IGF-1 deficiency in renal failure

Functional consequences of IGFBP excess—lessons from transgenic mice

“Missing” inhibitors of calcification: general aspects and implications in renal failure

Long-term use of recombinant human growth hormone in pediatric allograft recipients: a report of the NAPRTCS Transplant Registry

Genetic regulation of bone mass: from bone density to bone strength

Genomic and non-genomic actions of sex steroids in the growth plate

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie